TABLE 6.  Studies of MAOIs in major depression patients resistant to TCAs

 

Ref.

Sample

Medication and designa

Medication resistant toa

Results

Himmelhoch et

al. (44)

21 depressed

patients (13 BP,

11UP)

Tranycypromine (30 mg)

added to lithium; open

trial; ? duration

Recent (11) or past (8) trials TCA

16 of 21 (76%)

responders

Price et al. (82)

12 depressed

inpatients (6

psychotic UP, 2

BP)

Tranycypromine (30-60

mg) added to Li; open

crossover with blinded

rater; 4 or more weeks

Lithium added to

desipramine or

adinazolam or

bupropion

8 of 12 (67%)

responders

Georgotas et al.

(36)

20 depressed, UP

patients

Phenelzine (15-75 mg);

open crossover, 2-7

weeks

Imipramine 150-300 mg

or equivalent for 1-8

months

11 of 20 (55%)

responders

Nolen et al. (69)

26 depressed, UP

patients

Tranycypromine (82 mg)

or L-5HTP; open

randomized crossover,

4weeks

Imipramine > 150 mg or

equivalent followed

by trials oxaprotiline,

fluvoxamine, and

sleep deprivation

TRP: 7 of 14 (50%)

responders

(L-5HTP; 0 of 12

responders)

TRP > L-5HTP

Nolen et al. (67)

13 depressed, UP

patients

Tranycypromine (71 mg)

or nomifensine; double

blind randomized

crossover, 4 weeks

Imipramine > 150 mg

followed by trials of

oxaprotiline,

fluvoxamine, and

sleep deprivation

TRP; 4/8 (50%)

responders

nomifensine: 0/5

responders

TRP > NOM

Nolen et al. (70)

39 major depression

inpatients (31 UP,

8 BP)

Brofaramine (218 mg;

n = 22),

tranylcypromine

(85 mg; n = 17)

Prospective trial of

nortriptyline or

maprotiline

TRP 10/17 (59%)

BRO: 13/22

(59%) BRO

better tolerated

than TRP.

Ryan et al. (88))

23 major depression

adolescent

outpatients, ages

11-18

Phenelzine (n = 1 alone;

+ TCA, n = 7)

tranylcypromine (n = 3)

alone; + TCA, n = 12);

open trial; ? duration

Adequate doses of

TCAs for {ewc MVIMG, MVIMAGE,!greateq.bmp} 6 weeks

12 of 23 (56%)

responders

McGrath et al

(58)

46 depressed

outpatients, UP

(atypical)

depression

Phenelzine (60-90 mg);

double blind randomized

crossover, 6 weeks

Imipramine (200-300

mg)  for 6 weeks

31 of  46 (67%)

responders

PHZ > IMI

Thase et al.

(107)

42 patients

outpatients, UP

(atypical)

depression

Phenelzine (n = 4; 60 mg)

or tranylcypromine (38.5

mg); open crossover, 6

weeks

Imipramine (257 mg)

and interpersonal

psychotherapy

17 of 26 (65%)

responders

Thase et al.

(108)

12 patients with

anergic BP

depression

Tranylcypromine (30-60

mg), double blind,

randomized crossover, 6 weeks

Imipramine (242 mg/

day)

9 of 12 (75%)

responders

TRP > IMI

 

   Adapted from Devlin and Walsh (24).

   aDosage refers to mean prescribed dosage, where provided, or to dosage range.

 
Back to Chapter

published 2000